Get the Stockscreener App
9.43
2.06%
0.19
Design Therapeutics Inc stock is traded at $9.43, with a volume of 136.79K.
It is up +2.06% in the last 24 hours and up +23.92% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$9.24
Open:
$9.3
24h Volume:
136.79K
Relative Volume:
0.47
Market Cap:
$537.17M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-7.8583
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
-3.48%
1M Performance:
+23.92%
6M Performance:
+141.18%
1Y Performance:
+53.58%
1-Day Range:
$9.23
$9.56
1-Week Range:
$9.00
$10.18
52-Week Range:
$2.60
$10.31
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
9.43 | 526.35M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | Craig Hallum | Buy |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-20-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 5.8%Time to Sell? - MarketBeat
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $14.00 - Defense World
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why retail investors pile into Design Therapeutics Inc. stockJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress By Investing.com - Investing.com South Africa
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7 - MarketScreener
Will Design Therapeutics Inc. stock deliver shareholder valueWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Design Therapeutics (DSGN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Yahoo Finance
How Design Therapeutics Inc. stock performs in weak economyNew Guidance & Safe Entry Point Alerts - Newser
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Will Aries Agro Limited Stock Benefit From Industry Trends in YEARSupport Level Holds & Free Double Digit Growth Tips - earlytimes.in
How sustainable is Design Therapeutics Inc. stock dividend payoutWeekly Trend Summary & Breakout Confirmation Alerts - BỘ NỘI VỤ
Design Therapeutics (NASDAQ:DSGN) Trading Up 9%What's Next? - MarketBeat
Why Design Therapeutics Inc. stock is rated strong buyWeekly Market Report & Consistent Income Trade Recommendations - BỘ NỘI VỤ
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Design Therapeutics (Nasdaq: DSGN) to Participate in Piper Sandler and Evercore 2025 Events - Stock Titan
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - simplywall.st
Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
RBC Capital Upgrades Design Therapeutics (DSGN) - Nasdaq
Design Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - Markets Financial Content
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says - MarketScreener
Design Therapeutics stock up as RBC upgrades (DSGN:NASDAQ) - Seeking Alpha
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - Benzinga
Design Therapeutics : DSGN - 24/7 Wall St.
Design Therapeutics stock rating upgraded by RBC Capital on improved outlook - Investing.com Nigeria
RBC Upgrades Design Therapeutics to Outperform From Sector Perform, Boosts Price Target to $13 From $6, Keeps Speculative Risk - MarketScreener
Can Design Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Breakouts & Safe Entry Point Identification - newser.com
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global - openPR.com
Why retail investors favor Design Therapeutics Inc. stockJuly 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Is Design Therapeutics Inc. stock poised for growthTrade Analysis Summary & Safe Swing Trade Setups - newser.com
How to interpret RSI for Design Therapeutics Inc. stock2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Can Design Therapeutics Inc. stock sustain institutional interest - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio chartsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Technical signs of recovery in Design Therapeutics Inc.Weekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):